Aberrant crypt foci (ACF) are not surrogate biomarkers of sporadic adenoma prevention with celecoxib: Results from the Adenoma Prevention with Celecoxib (APC) trial

被引：0
|
作者：
Cho, Nancy L. [1 ]
Redston, Mark [1 ]
Zauber, Ann G. [2 ]
Carothers, Adelaide M. [1 ]
Hornick, Jason L. [1 ]
Wilton, Andrew [3 ]
Sontag, Stephen [4 ]
Nishioka, Norman [5 ]
Giardiello, Frances [6 ]
Saltzman, John R. [1 ]
Gostout, Chris [7 ]
Eagle, Craig J. [8 ]
Hawk, Ernest T. [9 ]
Bertagnolli, Monica M. [1 ]
机构：
[1] Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[3] Inst Clin Evaluat Sci, Toronto, ON, Canada
[4] Hines Vet Adm Ctr, Hines, IL USA
[5] Massachusetts Gen Hosp, Boston, MA 02114 USA
[6] Johns Hopkins Sch Med, Baltimore, MD USA
[7] Mayo Clin, Rochester, MN USA
[8] Pfizer Inc, New York, NY USA
[9] NCI, Bethesda, MD 20892 USA
来源：
CANCER RESEARCH | 2008年 / 68卷 / 09期
关键词：
D O I：
10.1158/1538-7445.AM2008-LB-242
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-242
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Comment re: "Sporadic Aberrant Crypt Foci Are Not a Surrogate Endpoint for Colorectal Adenoma Prevention" and "Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial"
    Stevens, Richard G.
    Pretlow, Theresa P.
    Hurlstone, D. Paul
    Giardina, Charles
    Rosenberg, Daniel W.
    CANCER PREVENTION RESEARCH, 2008, 1 (03) : 215 - U70
  • [2] Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial
    Cho, Nancy L.
    Redston, Mark
    Zauber, Ann G.
    Carothers, Adelaide M.
    Hornick, Jason
    Wilton, Andrew
    Sontag, Stephen
    Nishioka, Norman
    Giardiello, Francis M.
    Saltzman, John R.
    Gostout, Chris
    Eagle, Craig J.
    Hawk, Ernest T.
    Bertagnolli, Monica M.
    CANCER PREVENTION RESEARCH, 2008, 1 (01) : 21 - 31
  • [3] Celecoxib reduces formation of sporadic adenomas: results from the adenoma prevention with celecoxib (APC) trial
    Macrae, F.
    Jones, I. T.
    Pizzey, C.
    Bertagnolli, M.
    Hawk, E.
    Eagle, C.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A264 - A264
  • [4] Sporadic Aberrant Crypt Foci Are Not a Surrogate Endpoint for Colorectal Adenoma Prevention
    Lance, Peter
    Hamilton, Stanley R.
    CANCER PREVENTION RESEARCH, 2008, 1 (01) : 4 - 8
  • [5] Statin use and colorectal adenoma risk: Results from the Adenoma Prevention with Celecoxib (APC) trial
    Bertagnolli, Monica Marie
    Hsu, Meier
    Hawk, Ernest T.
    Eagle, Craig J.
    Zauber, Ann G.
    CANCER RESEARCH, 2010, 70
  • [6] The Adenoma Prevention with Celecoxib (APC) trial: Five-year efficacy and safety results
    Bertagnolli, Monica M.
    Zauber, Ann G.
    Hawk, Ernest T.
    CANCER RESEARCH, 2008, 68 (09)
  • [7] Statin Use and Colorectal Adenoma Risk: Results from the Adenoma Prevention with Celecoxib Trial
    Bertagnolli, Monica M.
    Hsu, Meier
    Hawk, Ernest T.
    Eagle, Craig J.
    Zauber, Ann G.
    CANCER PREVENTION RESEARCH, 2010, 3 (05) : 588 - 596
  • [8] The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: Stepping stones to progress
    Hawk, Ernest
    Viner, Jaye L.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2007, 16 (02) : 185 - 187
  • [9] Celecoxib and refecoxib in the prevention of azoxymethane-induced formation of aberrant crypt foci in mice
    Ramos, Gliceria B.
    De Vera, Miriam P.
    Tanaeli, Susano B.
    Bayot, Kimberly V.
    Caling, Joanne R.
    Espinosa, Karenina S.
    Reinos, Stefanie R.
    Su, Glenn L. Sia
    Herrera, Annabelle A.
    ASIA LIFE SCIENCES, 2010, 19 (02): : 419 - 428
  • [10] Insights From the Adenoma Prevention With Celecoxib Trial and Risk for Cardiovascular Adverse Events
    Kraus, Sarah
    Arber, Nadir
    CURRENT COLORECTAL CANCER REPORTS, 2010, 6 (01) : 1 - 3
12345